Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime/Avibactam Administration Regimens in Severe Infection
NCT06528028Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + avibactam in Gram-negative bacterial infection, sponsored by Nanjing Drum-Tower Hospital. Started Jul 2024; status: recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT06528028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528028.